Keyphrases
Multiple Sclerosis Treatment
100%
Multiple Sclerosis
57%
B Cells
42%
Anti-CD20 Antibody
42%
Relapsing-remitting multiple Sclerosis
28%
Gadolinium-enhancing Lesions
28%
Placebo
28%
Multicenter Trial
14%
Progressive multiple Sclerosis
14%
Cell Secretion
14%
Two-dose
14%
Randomized Placebo-controlled Trial
14%
Relative Reduction
14%
Disease Activity
14%
Serious Infection
14%
Opportunistic Infections
14%
Intramuscularly
14%
Autoantibodies
14%
Progressive multifocal Leukoencephalopathy
14%
Magnetic Resonance Imaging
14%
Rituximab
14%
Multiple Primary
14%
Adverse Effects
14%
Interferon beta-1a
14%
Ongoing Clinical Trials
14%
T Cells
14%
Myelin
14%
Relapsing-remitting
14%
Monoclonal Antibody
14%
Infusion Reaction
14%
Armamentarium
14%
Placebo-controlled
14%
Phase II Trial
14%
Inflammatory Cytokines
14%
Humanized
14%
Autoimmune Disease
14%
Immunology and Microbiology
Treatment of Multiple Sclerosis
100%
Multiple Sclerosis
71%
Rituximab
42%
B Cell
42%
Monoclonal Antibody
28%
Relapsing Remitting Multiple Sclerosis
28%
Interferon Beta 1a
14%
Arm
14%
Ofatumumab
14%
Autoimmune Disease
14%
Cellular Secretion
14%
Proinflammatory Cytokine
14%
Autoantibody
14%
Myelin
14%
Primary Progressive Multiple Sclerosis
14%
Magnetic Resonance Imaging
14%
CD20 Antibody
14%
Opportunistic Infection
14%
T Cell
14%
Neuroscience
Ocrelizumab
100%
CD20 Antibody
14%